摘要
目的探讨E26 transformation specific-1(Ets-1)、CD44V6在宫颈腺癌组织中的表达及临床意义,并分析两者之间的关系。方法采用免疫组织化学(EnVisionTM)法分别检测Ets-1、CD44V6在宫颈腺癌组织、癌旁组织中的表达。结果 Ets-1在宫颈腺癌组织、癌旁组织中的阳性表达率分别为52.50%、7.50%,两组之间差异有统计学意义(χ2=23.04,P<0.01);CD44V6在宫颈腺癌组织、癌旁组织中的阳性表达率分别为55.00%、12.50%,两组之间差异有统计学意义(χ2=19.93,P<0.01)。Ets-1的阳性表达与肿瘤大小、TNM分期、淋巴结转移、远处脏器转移有关,差异均有统计学意义(P<0.05),但与年龄、组织学类型无关,差异无统计学意义(P>0.05);CD44V6的阳性表达与TNM分期、淋巴结转移、远处脏器转移有关,差异均有统计学意义(P<0.05),但与肿瘤大小、年龄、组织学类型无关,差异无统计学意义(P>0.05)。Ets-1在宫颈腺癌组织中的表达与CD44V6的表达之间呈显著正相关(r=0.85,P<0.01)。结论 Ets-1、CD44V6在宫颈腺癌组织中呈现过表达,因而,检测两者可反映癌细胞浸润转移的风险。
Objective To investigate the expression of E26 transformation specific-1 （Etsl） and CD,~V6 in cervical adenocarcinoma and their clinical significance, and to analyze the relationship between them. Methods The expression of Ets I and CD^V6 was respectively detected by immunohistochemisty （EnVisionTM） in cervical adenoear- cinoma and cancer side. Results The positive expression rate of Etsl protein in cervical adenocarcinoma and cancer side was 52.50%, 7.50%, respectively, with statistically significant difference between them （gz=-23.04, P〈0.01）. The positive expression rate of CDuV6 protein in cervical adenocarcinoma and cancer side was 55.00%, 12.50%, respec- tively, with statistically significant difference between them （g2=19.93, P〈0.01）. The positive expression of Etsl was related to tumor size, TNM staging, lymph node metastasis and distant place organ metastasis （P〈 0.05）, but not to age and histological type （P〉0.05）. The positive expression of CD44V6 was related to TNM staging, lymph node metastasis and distant place organ metastasis （P〈0.05）, but not to tumor size, age and his- tological type （P〉0.05）. The expression between Etsl and CD,V6 in cervical adenocarcinoma was positively correlated （r=0.85, P〈0.01）. Conclusion Etsl and CD^V6 are overexpressed in cervical adenocarcinoma. There- fore. testing the two indicators max/reflect the risk of cancer cell infiltration and metastasis.
出处
《海南医学》
CAS
2013年第23期3446-3448,共3页
Hainan Medical Journal
关键词
宫颈腺癌
ETS1
CD44V6
免疫组织化学
Cervical adenocarcinoma
E26 transformation specific-1 （Etsl）
CD.V6
Immunohistoehemisty
